<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01319539</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2011-02513</org_study_id>
    <secondary_id>NCI-2011-02513</secondary_id>
    <secondary_id>CDR0000696821</secondary_id>
    <secondary_id>AECM-AAAF3912</secondary_id>
    <secondary_id>8740</secondary_id>
    <secondary_id>N01CM62204</secondary_id>
    <secondary_id>P30CA013330</secondary_id>
    <nct_id>NCT01319539</nct_id>
  </id_info>
  <brief_title>MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer</brief_title>
  <official_title>Pre-surgical Evaluation of MK-2206 in Patients With Operable Invasive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase II trial is studies how well Akt inhibitor MK2206 works in treating patients with&#xD;
      stage I-III breast cancer that can be removed by surgery. Akt inhibitor MK2206 may stop the&#xD;
      growth of tumor cells by blocking some of the enzymes needed for cell growth.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To assess for a decrease in phosphorylated (phospho)-protein kinase B (Akt) (Ser^473)&#xD;
      levels in tissue after a pre-surgical trial of weekly MK2206 (Akt inhibitor MK2206) (2 doses)&#xD;
      in patients with operable invasive breast cancer.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the effects of MK2206 on the immunohistochemical expression of other&#xD;
      phosphatidylinositide 3-kinase (PI3K)/AKT pathway biomarkers on pre-and post-MK2206 tumor&#xD;
      tissue, such as phospho-S6 kinase.&#xD;
&#xD;
      II. To assess modulation of PI3K/AKT signaling following MK2206 use with reverse-phase&#xD;
      protein microarray analysis.&#xD;
&#xD;
      III. To explore whether phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit&#xD;
      alpha (PIK3CA) mutations demonstrate different modulation of PI3K/Akt-pathway signaling as&#xD;
      compared to tumors with loss of phosphatase and tensin homolog (PTEN).&#xD;
&#xD;
      IV. To explore whether MK2206 alters PI3K/Akt pathway signaling differently in hormone&#xD;
      receptor-positive/human epidermal growth factor receptor (HER)2-negative tumors, as compared&#xD;
      to triple-negative or HER2-positive breast cancers.&#xD;
&#xD;
      V. To evaluate whether tumor proliferation, as measured by Ki-67 staining of breast tumor&#xD;
      cells, is reduced in patients taking MK2206 pre-surgically and correlate Ki-67 modulation&#xD;
      with changes in PI3K/AKT signaling.&#xD;
&#xD;
      VI. To determine safety and tolerability of MK2206 in patients with early-stage breast&#xD;
      cancer.&#xD;
&#xD;
      VII. To collect fasting blood for evaluation of predictive markers of drug effect, such as&#xD;
      markers in the insulin growth-factor receptor pathway (i.e., fasting insulin, c-peptide,&#xD;
      insulin-like growth factor [IGF]-1, and IGF binding protein [BP]-1 and 3), as well as&#xD;
      modulation of phospho-markers in peripheral blood mononuclear cells.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive Akt inhibitor MK2206 orally (PO) on days -9 and -2, and undergo segmental&#xD;
      resection or total mastectomy on day 0.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 4 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    terminated early, due to toxicity&#xD;
  </why_stopped>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in pAKT Levels</measure>
    <time_frame>Baseline, 2 weeks (Day 0 - surgery)</time_frame>
    <description>This is designed to evaluate response to therapy - comparing changes within group (example: invasive pre-MK-2206-treated core versus post-MK-2206-treated surgical tissue).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in pS6 Levels</measure>
    <time_frame>Baseline, 2 weeks (Day 0 - surgery)</time_frame>
    <description>This is designed to evaluate response to therapy - comparing changes within group (example: invasive pre-MK-2206-treated core versus post-MK-2206-treated surgical tissue).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ki-67 Expression</measure>
    <time_frame>Baseline, 2 weeks (Day 0 - surgery)</time_frame>
    <description>This is designed to evaluate response to therapy - comparing changes within group (example: invasive pre-MK-2206-treated core versus post-MK-2206-treated surgical tissue).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Estrogen Receptor Negative</condition>
  <condition>Estrogen Receptor Positive</condition>
  <condition>HER2/Neu Negative</condition>
  <condition>HER2/Neu Positive</condition>
  <condition>Progesterone Receptor Negative</condition>
  <condition>Progesterone Receptor Positive</condition>
  <condition>Stage IA Breast Cancer</condition>
  <condition>Stage IB Breast Cancer</condition>
  <condition>Stage IIA Breast Cancer</condition>
  <condition>Stage IIB Breast Cancer</condition>
  <condition>Stage IIIA Breast Cancer</condition>
  <condition>Stage IIIB Breast Cancer</condition>
  <condition>Stage IIIC Breast Cancer</condition>
  <condition>Triple-Negative Breast Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment (Akt inhibitor MK2206)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive Akt inhibitor MK2206 PO on days -9 and -2, and undergo segmental resection or total mastectomy (therapeutic conventional surgery) on day 0. Patient samples will be processed for pharmacological study and laboratory biomarker analysis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Akt Inhibitor MK2206</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (Akt inhibitor MK2206)</arm_group_label>
    <other_name>MK2206</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Therapeutic Conventional Surgery</intervention_name>
    <description>Undergo surgery</description>
    <arm_group_label>Treatment (Akt inhibitor MK2206)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (Akt inhibitor MK2206)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (Akt inhibitor MK2206)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically-confirmed operable invasive breast cancer and have&#xD;
             undergone core needle biopsy with an anticipated surgical resection for residual&#xD;
             disease after enrollment&#xD;
&#xD;
          -  Patients must have clinical stage I-III invasive breast (invasive tumor must be&#xD;
             clinically at least &gt;= T1c by radiograph or palpation)&#xD;
&#xD;
          -  Patients must have available tissue from core biopsies for biomarker assessment; it is&#xD;
             recommended that at least 4 cores be performed with 12 gauge (or smaller gauge)&#xD;
             needles; this includes cores underneath ultrasound-guidance&#xD;
&#xD;
          -  Patients are planning to undergo surgical treatment with either segmental resection or&#xD;
             total mastectomy (required: 2 doses of weekly MK-2206 prior to surgery; the first dose&#xD;
             will be at day -9 [+/- 1 day] and second dose at day -2 [+/- 1 day] in relation to&#xD;
             surgery [day 0])&#xD;
&#xD;
          -  Patients may have a history of contralateral breast cancer, provided there is no&#xD;
             evidence of recurrence of the initial primary breast cancer&#xD;
&#xD;
          -  Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of&#xD;
             0-1 (Karnofsky &gt;= 80%)&#xD;
&#xD;
          -  Leukocytes &gt;= 3,000/ul within 28 days of registration&#xD;
&#xD;
          -  Platelets &gt;= 100,000 /uL within 28 days of registration&#xD;
&#xD;
          -  Hemoglobin (Hgb) &gt;= 9 g/dL within 28 days of registration&#xD;
&#xD;
          -  Creatinine =&lt; 1.5 x upper limit of normal (ULN) within 28 days of registration&#xD;
&#xD;
          -  Prothrombin time (PT), partial thromboplastin time (PTT) =&lt; 1.2 x ULN within 28 days&#xD;
             of registration&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x ULN within 28 days of registration&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) &lt; 2.5 x ULN within&#xD;
             28 days of registration&#xD;
&#xD;
          -  Patients of childbearing potential must have a negative serum or urine pregnancy test&#xD;
             beta-human chorionic gonadotropin (Î²-hCG) within 72 hours prior to receiving the first&#xD;
             dose of study medication&#xD;
&#xD;
          -  Women of childbearing potential and men must use two forms of contraception (hormonal&#xD;
             or barrier method of birth control; abstinence) prior to study entry and for the&#xD;
             duration of study participation; should a woman become pregnant or suspect she is&#xD;
             pregnant while she or her partner is participating in this study, the patient should&#xD;
             inform the treating physician immediately&#xD;
&#xD;
          -  Patient must be able to swallow oral tablets&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
          -  Patients must agree to biomarker assessment of pre-treatment diagnostic core biopsy&#xD;
             tissue and the surgical resection tissue (i.e. excision or mastectomy); also, must&#xD;
             agree to pre- and post-treatment fasting blood biomarker collection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients may not have any known evidence of distant metastatic disease (i.e., lung,&#xD;
             liver, bone, or brain metastases) or locally recurrent breast cancer&#xD;
&#xD;
          -  Patients with inflammatory breast cancer are not eligible&#xD;
&#xD;
          -  Patients with prior chemotherapy or radiation therapy within 6 months of study entry&#xD;
             are not eligible (i.e. patient who have received neoadjuvant therapy are not eligible)&#xD;
&#xD;
          -  Patients may not be receiving any other investigational agents, including other&#xD;
             inhibitors of PI3K, Akt, or mammalian target of rapamycin (mTOR)&#xD;
&#xD;
          -  Men diagnosed with breast cancer&#xD;
&#xD;
          -  Patients may not have a history of allergic reactions attributed to compounds of&#xD;
             similar chemical or biologic composition to MK-2206 used in the study&#xD;
&#xD;
          -  Patients with known diabetes which is poorly controlled diabetes (hemoglobin A1c&#xD;
             [HBA1C] &gt;= 8%) should be excluded; if patient is taking metformin, must have been&#xD;
             taking this medication for &gt; 3 months, as metformin is thought to impact PI3K/Akt&#xD;
             signaling&#xD;
&#xD;
          -  Baseline corrected QT interval (QTc) &gt; 470 msec will exclude patients from entry on&#xD;
             study; patients with a baseline bundle branch block will be excluded&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          -  Pregnant women are excluded from this study; breastfeeding should be discontinued if&#xD;
             the mother is treated with MK2206&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral&#xD;
             therapy are ineligible&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin Kalinsky</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center - Moses Campus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine</name>
      <address>
        <city>The Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center - Moses Campus</name>
      <address>
        <city>The Bronx</city>
        <state>New York</state>
        <zip>10467-2490</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>March 18, 2011</study_first_submitted>
  <study_first_submitted_qc>March 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2011</study_first_posted>
  <results_first_submitted>October 14, 2016</results_first_submitted>
  <results_first_submitted_qc>July 5, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 1, 2017</results_first_posted>
  <last_update_submitted>August 1, 2017</last_update_submitted>
  <last_update_submitted_qc>August 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>12 participants were enrolled between September 2011 and March 2013.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Akt Inhibitor MK2206)</title>
          <description>Patients receive Akt inhibitor MK2206 PO on days -9 and -2, and undergo segmental resection or total mastectomy on day 0.&#xD;
Akt Inhibitor MK2206: Given PO&#xD;
Therapeutic Conventional Surgery: Undergo surgery&#xD;
Pharmacological Study: Correlative studies&#xD;
Laboratory Biomarker Analysis: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Akt Inhibitor MK2206)</title>
          <description>Patients receive Akt inhibitor MK2206 PO on days -9 and -2, and undergo segmental resection or total mastectomy on day 0.&#xD;
Akt Inhibitor MK2206: Given PO&#xD;
Therapeutic Conventional Surgery: Undergo surgery&#xD;
Pharmacological Study: Correlative studies&#xD;
Laboratory Biomarker Analysis: Correlative studies</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.2" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hispanic White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hispanic Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in pAKT Levels</title>
        <description>This is designed to evaluate response to therapy - comparing changes within group (example: invasive pre-MK-2206-treated core versus post-MK-2206-treated surgical tissue).</description>
        <time_frame>Baseline, 2 weeks (Day 0 - surgery)</time_frame>
        <population>Of the 12 participants enrolled and received study treatment, there were 7 participants with evaluable matched core and surgical specimen tissue.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Akt Inhibitor MK2206)</title>
            <description>Patients receive Akt inhibitor MK2206 PO on days -9 and -2, and undergo segmental resection or total mastectomy on day 0.&#xD;
Akt Inhibitor MK2206: Given PO&#xD;
Therapeutic Conventional Surgery: Undergo surgery&#xD;
Pharmacological Study: Correlative studies&#xD;
Laboratory Biomarker Analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Change in pAKT Levels</title>
          <description>This is designed to evaluate response to therapy - comparing changes within group (example: invasive pre-MK-2206-treated core versus post-MK-2206-treated surgical tissue).</description>
          <population>Of the 12 participants enrolled and received study treatment, there were 7 participants with evaluable matched core and surgical specimen tissue.</population>
          <units>percentage of cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Core</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" spread="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in pS6 Levels</title>
        <description>This is designed to evaluate response to therapy - comparing changes within group (example: invasive pre-MK-2206-treated core versus post-MK-2206-treated surgical tissue).</description>
        <time_frame>Baseline, 2 weeks (Day 0 - surgery)</time_frame>
        <population>Of the 12 participants enrolled and received study treatment, there were 7 participants with evaluable matched core and surgical specimen tissue.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Akt Inhibitor MK2206)</title>
            <description>Patients receive Akt inhibitor MK2206 PO on days -9 and -2, and undergo segmental resection or total mastectomy on day 0.&#xD;
Akt Inhibitor MK2206: Given PO&#xD;
Therapeutic Conventional Surgery: Undergo surgery&#xD;
Pharmacological Study: Correlative studies&#xD;
Laboratory Biomarker Analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Change in pS6 Levels</title>
          <description>This is designed to evaluate response to therapy - comparing changes within group (example: invasive pre-MK-2206-treated core versus post-MK-2206-treated surgical tissue).</description>
          <population>Of the 12 participants enrolled and received study treatment, there were 7 participants with evaluable matched core and surgical specimen tissue.</population>
          <units>percentage of cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Core</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" spread="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31" spread="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Ki-67 Expression</title>
        <description>This is designed to evaluate response to therapy - comparing changes within group (example: invasive pre-MK-2206-treated core versus post-MK-2206-treated surgical tissue).</description>
        <time_frame>Baseline, 2 weeks (Day 0 - surgery)</time_frame>
        <population>Of the 12 participants enrolled and received study treatment, there were 7 participants with evaluable matched core and surgical specimen tissue.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Akt Inhibitor MK2206)</title>
            <description>Patients receive Akt inhibitor MK2206 PO on days -9 and -2, and undergo segmental resection or total mastectomy on day 0.&#xD;
Akt Inhibitor MK2206: Given PO&#xD;
Therapeutic Conventional Surgery: Undergo surgery&#xD;
Pharmacological Study: Correlative studies&#xD;
Laboratory Biomarker Analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Ki-67 Expression</title>
          <description>This is designed to evaluate response to therapy - comparing changes within group (example: invasive pre-MK-2206-treated core versus post-MK-2206-treated surgical tissue).</description>
          <population>Of the 12 participants enrolled and received study treatment, there were 7 participants with evaluable matched core and surgical specimen tissue.</population>
          <units>percentage of cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Core</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 weeks</time_frame>
      <desc>The definition of adverse event and/or serious adverse event, used to collect adverse event information, does not differ from the ClinicalTrials.gov definitions.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment (MK2206) Dose Level 200mg</title>
          <description>Patients receive Akt inhibitor MK2206 PO on days -9 and -2, and undergo segmental resection or total mastectomy on day 0.</description>
        </group>
        <group group_id="E2">
          <title>Treatment (MK2206) Dose Level 135mg</title>
          <description>Patients receive Akt inhibitor MK2206 PO on days -9 and -2, and undergo segmental resection or total mastectomy on day 0.</description>
        </group>
        <group group_id="E3">
          <title>Treatment (MK2206) Dose Level 90mg</title>
          <description>Patients receive Akt inhibitor MK2206 PO on days -9 and -2, and undergo segmental resection or total mastectomy on day 0.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <description>Participant also experienced Rash</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash, Grade 3</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis, Grade 1</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Mucositis, Grade 2</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash, Grade 2</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rash, Grade 3</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pruritus, Grade 1</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pruritus, Grade 3</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kevin Kalinsky, MD</name_or_title>
      <organization>Columbia University Medical Center</organization>
      <phone>212-305-1945</phone>
      <email>kk2693@cumc.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

